how big is Zydus Wellness?

As of Jun 06, Zydus Wellness Ltd has a market capitalization of 12,364.68 Cr, with net sales of 2708.90 Cr and a net profit of 346.90 Cr for the latest four quarters.

Market Cap: Zydus Wellness Ltd has a market capitalization of 12,364.68 Cr and is classified as a Mid Cap company as of Jun 06.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Zydus Wellness reported net sales of 2708.90 Cr and a net profit of 346.90 Cr. This data is consolidated.<BR><BR>Balance Sheet Snapshot: The balance sheet data is consolidated for the latest annual period ending in Mar'24. Shareholder's funds are reported at 5,357.50 Cr, and total assets amount to 5,992.10 Cr.

Who are in the management team of Zydus Wellness?

As of March 2023, the management team of Zydus Wellness includes Tarun Arora (CEO), Sharvil P Patel (Chairman), and several non-executive and independent directors, overseeing the company's operations and strategic direction.

As of March 2023, the management team of Zydus Wellness includes the following members:<BR><BR>1. Ganesh N Nayak - Non-Executive & Non-Independent Director<BR>2. Sharvil P Patel - Chairman (Non-Executive)<BR>3. Tarun Arora - Whole Time Director & CEO<BR>4. Kulin S Lalbhai - Non-Executive & Independent Director<BR>5. Ashish Bhargava - Nominee<BR>6. Dharmishta N Rawal - Non-Executive & Independent Director<BR>7. Srivishnu Raju Nandyala - Non-Executive & Independent Director<BR>8. Nandish P. Joshi - Company Secretary & Compliance Officer<BR>9. Akhil A. Monappa - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

When is the next results date for Zydus Wellness?

No Upcoming Board Meetings

Has Zydus Wellness declared dividend?

Zydus Wellness Ltd has declared a 50% dividend, amounting to ₹5 per share, with an ex-date of July 19, 2024. The dividend yield is 0.26%, and total returns over the past five years stand at 51.68%.

Zydus Wellness Ltd has declared a 50% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 5<BR>- Ex-date: 19 Jul 24<BR><BR>Dividend Yield: 0.26%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -4.86%, the dividend return was 0%, resulting in a total return of -4.86%.<BR><BR>Over the past year, the price return was 3.51%, the dividend return was 0.26%, leading to a total return of 3.77%.<BR><BR>In the 2-year period, the price return was 28.84%, the dividend return was 0.67%, culminating in a total return of 29.51%.<BR><BR>For the 3-year period, the price return was 23.44%, the dividend return was 0.97%, resulting in a total return of 24.41%.<BR><BR>In the last 4 years, the price return was -7.19%, the dividend return was 0.96%, leading to a total return of -6.23%.<BR><BR>Over the past 5 years, the price return was 50.14%, the dividend return was 1.54%, resulting in a total return of 51.68%.<BR><BR>Overall, Zydus Wellness has declared a dividend, which contributes to a modest dividend yield. The total returns over various periods show a mix of positive and negative performance, with the 5-year period reflecting the strongest total return.

Who are the peers of the Zydus Wellness?

Zydus Wellness peers include Hind. Unilever, ITC, Nestle India, Britannia Inds., and others, with average management risk and below-average growth. Its 1-year return is 14.09%, higher than Honasa Consumer's -32.21% but lower than Manorama Indust.'s 129.10%.

Peers: The peers of Zydus Wellness are Hind. Unilever, ITC, Nestle India, Britannia Inds., Godrej Consumer, CCL Products, Avanti Feeds, Honasa Consumer, Mrs Bectors, and Manorama Indust.<BR><BR>Quality Snapshot: Excellent management risk is observed at ITC, Nestle India, and Britannia Inds., while Good management risk is found at Hind. Unilever, Godrej Consumer, CCL Products, Avanti Feeds, and Mrs Bectors. Average management risk is present at Zydus Wellness and Honasa Consumer. All peers exhibit Below Average growth except for Manorama Indust., which shows Excellent growth, while Zydus Wellness, Hind. Unilever, ITC, Nestle India, Britannia Inds., Godrej Consumer, CCL Products, Avanti Feeds, Honasa Consumer, and Mrs Bectors show Below Average growth. Excellent capital structure is noted for ITC, Nestle India, Britannia Inds., Godrej Consumer, Zydus Wellness, Avanti Feeds, and Mrs Bectors, while CCL Products has Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Manorama Indust. at 129.10%, while the lowest is Honasa Consumer at -32.21%. Zydus Wellness has a 1-year return of 14.09%, which is significantly higher than Honasa Consumer but lower than Manorama Indust. Additionally, the six-month returns for Honasa Consumer and Mrs Bectors are negative.

What does Zydus Wellness do?

Zydus Wellness Ltd is a Mid Cap FMCG company specializing in health and wellness products, with reported net sales of ₹9,131 Cr and a net profit of ₹1,719 Cr for the quarter ending March 2025. The company has a market cap of ₹12,843 Cr and key metrics include a P/E ratio of 37.00 and a dividend yield of 0.55%.

Overview:<BR>Zydus Wellness Ltd operates in the FMCG industry and is categorized as a Mid Cap company.<BR><BR>History:<BR>Zydus Wellness Limited was incorporated on November 1, 1994, originally as 'Carnation Health Foods Limited'. The company underwent several name changes, becoming 'Carnation Nutra-Analogue Foods Limited' before finally adopting its current name on January 5, 2009. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 9,131 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1,719 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 12,843 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 37.00 <BR>Industry P/E: 56 <BR>Dividend Yield: 0.55% <BR>Debt-Equity: 0.01 <BR>Return on Equity: 6.02% <BR>Price to Book: 2.26 <BR><BR>Contact Details:<BR>Address: Zydus Corporate Park S No 536, Sarkhej-Gandhinagar Highway Ahmedabad Gujarat : 382481 <BR>Tel: 91-79-67775888 <BR>Email: investor.grievance@zyduswellness.in <BR>Website: http://www.zyduswellness.in

Who are the top shareholders of the Zydus Wellness?

The top shareholders of Zydus Wellness include Zydus Lifesciences Limited with 57.59%, Threpsi Care LLP at 7.27%, and individual investors at 5.91%. Mutual funds hold 11.61%, while foreign institutional investors account for 3.29%, with no pledged promoter holdings reported.

The top shareholders of Zydus Wellness include Zydus Lifesciences Limited, which holds the largest stake at 57.59%. Other significant shareholders are Threpsi Care LLP, with a holding of 7.27%, and individual investors, who collectively own 5.91%. Additionally, mutual funds are represented through 13 schemes, accounting for 11.61% of the shares, while foreign institutional investors (FIIs) hold 3.29% through 101 different entities. There are no pledged promoter holdings reported.

Is Zydus Wellness technically bullish or bearish?

As of November 3, 2025, the trend is mildly bullish with daily moving averages supporting this view, but mixed signals from the MACD and KST suggest a cautious approach.

As of 3 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by the daily moving averages indicating bullish momentum. The weekly MACD is mildly bearish, while the monthly MACD remains bullish, suggesting mixed signals across time frames. Bollinger Bands are bullish on both weekly and monthly charts, reinforcing the positive outlook. However, the KST shows a bullish weekly trend but is mildly bearish monthly, indicating some caution. Overall, while there are bullish indicators, the mixed signals suggest a cautious approach.

Are Zydus Wellness latest results good or bad?

Zydus Wellness's latest results are concerning, showing a net loss of ₹52.80 crores in Q2 FY26, a 141.28% decline from the previous quarter, alongside a significant drop in operating margin to 3.58%. Despite a year-on-year revenue increase of 31.97%, the overall performance indicates serious profitability and operational challenges.

Zydus Wellness's latest results indicate a troubling performance. In Q2 FY26, the company reported a net loss of ₹52.80 crores, marking a significant decline of 141.28% compared to the previous quarter. This is the first quarterly loss in recent history, raising serious concerns about profitability.<BR><BR>While the revenue for the quarter was ₹650.50 crores, which is a year-on-year increase of 31.97%, it represents a substantial sequential decline of 24.44% from the previous quarter. The operating margin also collapsed to just 3.58%, down from 18.14% in Q1 FY26, highlighting severe operational challenges.<BR><BR>The company's return on equity (ROE) stands at a low 5.88%, significantly trailing industry peers, which typically achieve ROEs of 20-30%. This suggests inefficiencies in capital utilization and raises questions about the sustainability of its business model.<BR><BR>Overall, the financial metrics point to a deterioration in performance, with investor sentiment likely affected by the sharp decline in profitability and margins. The stock has also seen a decline of 7.63% over the past week, reflecting growing concerns among investors. Therefore, the latest results can be characterized as bad, with critical issues that the company needs to address moving forward.

Should I buy, sell or hold Zydus Wellness?

How has been the historical performance of Zydus Wellness?

Zydus Wellness has shown consistent growth in net sales and profits from March 2020 to March 2025, with net sales increasing from 1,766.82 Cr to 2,708.90 Cr and operating profit peaking at 393.30 Cr, despite some fluctuations in profit margins and cash flow. Total liabilities rose to 6,297.20 Cr, while cash flow from operations improved to 380.00 Cr.

Answer:<BR>The historical performance of Zydus Wellness shows a consistent growth trajectory in net sales and profit over the years, with notable fluctuations in profit margins and cash flow.<BR><BR>Breakdown:<BR>Zydus Wellness has demonstrated significant growth in net sales, increasing from 1,766.82 Cr in March 2020 to 2,708.90 Cr in March 2025. The total operating income has mirrored this growth, reaching 2,708.90 Cr in March 2025, up from 1,766.82 Cr in March 2020. The operating profit (PBDIT) has also shown an upward trend, with a peak of 393.30 Cr in March 2025, although it experienced some fluctuations in previous years. Profit before tax reached 358.80 Cr in March 2025, while profit after tax stood at 346.90 Cr, indicating a healthy profitability despite a slight decline from the previous year. The company’s total liabilities increased to 6,297.20 Cr in March 2025, up from 5,468.89 Cr in March 2020, reflecting a rise in both short-term and long-term borrowings. Cash flow from operating activities improved significantly to 380.00 Cr in March 2025, compared to 259.00 Cr in March 2020, although the net cash outflow was recorded at -13.00 Cr in March 2025. Overall, Zydus Wellness has shown resilience and growth in its financial performance over the years.

Is Zydus Wellness overvalued or undervalued?

As of November 6, 2025, Zydus Wellness is considered overvalued with a valuation grade of expensive, reflected by a PE ratio of 49.20 and a recent 1-week decline of 8.76%, despite a strong year-to-date return of 14.50%.

As of 6 November 2025, the valuation grade for Zydus Wellness has moved from fair to expensive, indicating a shift in its market perception. The company is currently considered overvalued. Key ratios include a PE ratio of 49.20, an EV to EBITDA of 44.54, and a Price to Book Value of 0.25, which suggest that the stock is trading at a premium compared to its earnings and asset value.<BR><BR>In comparison to its peers, Zydus Wellness has a lower PE ratio than Hindustan Unilever, which stands at 54.11, and Nestle India, which has a PE of 81.85. However, the overall valuation of Zydus Wellness remains expensive in the context of the FMCG sector, where many peers are also categorized as very expensive. Despite a strong year-to-date return of 14.50% compared to the Sensex's 6.62%, the stock's recent performance has been lackluster, with a 1-week decline of 8.76%, reinforcing the notion that it may be overvalued at current levels.

Why is Zydus Wellness falling/rising?

As of 04-Dec, Zydus Wellness Ltd's stock price is declining, currently at 417.35, with a total drop of -6.6% over the last eight days. Despite being above its 200-day moving average, it is below shorter-term averages, indicating short-term weakness, although investor participation has increased significantly.

As of 04-Dec, Zydus Wellness Ltd's stock price is falling, currently at 417.35, which reflects a change of -1.6 (-0.38%). The stock has been on a downward trend, experiencing consecutive losses for the last eight days, resulting in a total decline of -6.6% during this period. Additionally, over the past week, the stock has underperformed relative to the benchmark Sensex, which has only decreased by -0.53%, while Zydus Wellness has dropped by -3.63%. <BR><BR>In terms of moving averages, the stock is currently higher than its 200-day moving average but lower than its 5-day, 20-day, 50-day, and 100-day moving averages, indicating a short-term weakness. Despite this, there has been a notable increase in investor participation, with delivery volume rising by 78.82% against the 5-day average, suggesting some interest in the stock despite its recent performance. Overall, the combination of consecutive declines, underperformance against the benchmark, and unfavorable moving averages contributes to the current falling price of Zydus Wellness Ltd.

Which are the latest news on Zydus Wellness?